Highlights of the 8th international conference on vaccines for enteric diseases: The scottish encounter to defeat diarrheal diseases

Clinical and Vaccine Immunology

Volumn 23, Issue 4, 2016, Pages 272-281

  Tennant, Sharon M ^a   Steele, A Duncan ^b   Pasetti, Marcela F ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACE 527; CHOLERA VACCINE; ENTEROTOXIGENIC ESCHERICHIA COLI VACCINE; ESCHERICHIA COLI VACCINE; FLEXYN2A VACCINE; NOROVIRUS VACCINE; P2 VP8; ROTAVIRUS VACCINE; SALMONELLOSIS VACCINE; SHIGELLA VACCINE; TY21A VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG; VACCINE; VIRUS VACCINE; WRSS1 VACCINE;

ARTICLE; AWARENESS; BINDING ASSAY; CHOLERA; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENTEROTOXIGENIC ESCHERICHIA COLI; ENZYME LINKED IMMUNOSORBENT ASSAY; FINANCIAL MANAGEMENT; HEALTH CARE POLICY; HELICOBACTER INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; NONHUMAN; NOROVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; SCOTLAND; SHIGELLA; SINGLE DRUG DOSE; VACCINATION; DIAGNOSTIC TEST; ENTERITIS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOLECULAR DIAGNOSIS; PROCEDURES;

DIAGNOSTIC TESTS, ROUTINE; DIARRHEA; ENTERITIS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PREVALENCE; SCOTLAND; VACCINES;

EID: 84964800468     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00082-16     Document Type: Article

References (39)

1. WHO. 2015. WHO estimates of the global burden of foodborne diseases. Foodborne Disease Burden Epidemiology Reference Group 2007-2015. WHO, Geneva, Switzerland.
2. Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, Sur D, Breiman RF, Faruque AS, Zaidi AK, Saha D, Alonso PL, Tamboura B, Sanogo D, Onwuchekwa U, Manna B, Ramamurthy T, Kanungo S, Ochieng JB, Omore R, Oundo JO, Hossain A, Das SK, Ahmed S, Qureshi S, Quadri F, Adegbola RA, Antonio M, Hossain MJ, Akinsola A, Mandomando I, Nhampossa T, Acacio S, Biswas K, O'Reilly CE, Mintz ED, Berkeley LY, Muhsen K, Sommerfelt H, Robins-Browne RM, Levine MM. 2013. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 382:209-222. http://dx.doi.org/10.1016/S0140-6736(13)60844-2.
3. Lindsay B, Ochieng JB, Ikumapayi UN, Toure A, Ahmed D, Li S, Panchalingam S, Levine MM, Kotloff K, Rasko DA, Morris CR, Juma J, Fields BS, Dione M, Malle D, Becker SM, Houpt ER, Nataro JP, Sommerfelt H, Pop M, Oundo J, Antonio M, Hossain A, Tamboura B, Stine OC. 2013. Quantitative PCR for detection of Shigella improves ascertainment of Shigella burden in children with moderate-to-severe diarrhea in low-income countries. J Clin Microbiol 51:1740-1746. http://dx.doi.org/10.1128/JCM.02713-12.
4. Kampf MM, Braun M, Sirena D, Ihssen J, Thony-Meyer L, Ren Q. 2015. In vivo production of a novel glycoconjugate vaccine against Shigella flexneri 2a in recombinant Escherichia coli: identification of stimulating factors for in vivo glycosylation. Microb Cell Fact 14:12. http://dx.doi.org/10.1186/s12934-015-0195-7.
5. Gerke C, Colucci AM, Giannelli C, Sanzone S, Vitali CG, Sollai L, Rossi O, Martin LB, Auerbach J, Di CV, Saul A. 2015. Production of a Shigella sonnei vaccine based on generalized modules for membrane antigens (GMMA), 1790GAHB. PLoS One 10:e0134478. http://dx.doi.org/10.1371/journal.pone.0134478.
6. Cohen D, Green MS, Block C, Rouach T, Ofek I. 1988. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. J Infect Dis 157:1068-1071. http://dx.doi.org/10.1093/infdis/157.5.1068.
7. Cohen D, Block C, Green MS, Lowell G, Ofek I. 1989. Immunoglobulin M, A, and G antibody response to lipopolysaccharide O antigen in symptomatic and asymptomatic Shigella infections. J Clin Microbiol 27:162-167.
8. Kotloff KL, Taylor DN, Sztein MB, Wasserman SS, Losonsky GA, Nataro JP, Venkatesan M, Hartman A, Picking WD, Katz DE, Campbell JD, Levine MM, Hale TL. 2002. Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect Immun 70:2016-2021. http://dx.doi.org/10.1128/IAI.70.4.2016-2021.2002.
9. Zhang W, Sack DA. 2015. Current progress in developing subunit vaccines against enterotoxigenic Escherichia coli-Associated diarrhea. Clin Vaccine Immunol 22:983-991. http://dx.doi.org/10.1128/CVI.00224-15.
10. Harro C, Chakraborty S, Feller A, DeNearing B, Cage A, Ram M, Lundgren A, Svennerholm AM, Bourgeois AL, Walker RI, Sack DA. 2011. Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines. Clin Vaccine Immunol 18:1719-1727. http://dx.doi.org/10.1128/CVI.05194-11.
11. Chakraborty S, Harro C, DeNearing B, Ram M, Feller A, Cage A, Bauers N, Bourgeois AL, Walker R, Sack DA. 2015. Characterization of mucosal immune responses to enterotoxigenic Escherichia coli vaccine antigens in a human challenge model: response profiles after primary infection and homologous rechallenge with strain H10407. Clin Vaccine Immunol 23:55-64. http://dx.doi.org/10.1128/CVI.00617-15.
12. Darsley MJ, Chakraborty S, DeNearing B, Sack DA, Feller A, Buchwaldt C, Bourgeois AL, Walker R, Harro CD. 2012. The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease. Clin Vaccine Immunol 19:1921-1931. http://dx.doi.org/10.1128/CVI.00364-12.
13. Harro C, Sack D, Bourgeois AL, Walker R, DeNearing B, Feller A, Chakraborty S, Buchwaldt C, Darsley MJ. 2011. A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phase I trial in healthy adults. Clin Vaccine Immunol 18:2118-2127. http://dx.doi.org/10.1128/CVI.05342-11.
14. Lundgren A, Bourgeois L, Carlin N, Clements J, Gustafsson B, Hartford M, Holmgren J, Petzold M, Walker R, Svennerholm AM. 2014. Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebocontrolled phase I study. Vaccine 32:7077-7084. http://dx.doi.org/10.1016/j.vaccine.2014.10.069.
15. Kotloff KL, Simon JK, Pasetti MF, Sztein MB, Wooden SL, Livio S, Nataro JP, Blackwelder WC, Barry EM, Picking W, Levine MM. 2007. Safety and immunogenicity of CVD 1208S, a live, oral guaBA sen set Shigella flexneri 2a vaccine grown on animal-free media. Hum Vaccin 3:268-275. http://dx.doi.org/10.4161/hv.4746.
16. Abubakar A, Azman AS, Rumunu J, Ciglenecki I, Helderman T, West H, Lessler J, Sack DA, Martin S, Perea W, Legros D, Luquero FJ. 2015. The first use of the global oral cholera vaccine emergency stockpile: lessons from South Sudan. PLoS Med 12:e1001901. http://dx.doi.org/10.1371/journal.pmed.1001901.
17. Lewnard JA, Antillon M, Gonsalves G, Miller AM, Ko AI, Pitzer VE. 2016. Strategies to prevent cholera introduction during international personnel deployments: a computational modeling analysis based on the 2010 Haiti outbreak. PLoS Med 13:e1001947. http://dx.doi.org/10.1371/journal.pmed.1001947.
18. Azman AS, Luquero FJ, Ciglenecki I, Grais RF, Sack DA, Lessler J. 2015. The impact of a one-dose versus two-dose oral cholera vaccine regimen in outbreak settings: a modeling study. PLoS Med 12:e1001867. http://dx.doi.org/10.1371/journal.pmed.1001867.
19. Mengel MA. 2014. Cholera in Africa: new momentum in fighting an old problem. Trans R Soc Trop Med Hyg 108:391-392. http://dx.doi.org/10.1093/trstmh/tru077.
20. Debes AK, Ateudjieu J, Guenou E, Lopez AL, Bugayong MP, Retiban PJ, Garrine M, Mandomando I, Li S, Stine OC, Sack DA. 2016. Evaluation in Cameroon of a novel, simplified methodology to assist molecular microbiological analysis of V. cholerae in resource-limited settings. PLoS Negl Trop Dis 10:e0004307. http://dx.doi.org/10.1371/journal.pntd.0004307.
21. Debes AK, Ateudjieu J, Guenou E, Ebile W, Sonkoua IT, Njimbia AC, Steinwald P, Ram M, Sack DA. 11 January 2016. Clinical and environmental surveillance for Vibrio cholerae in resource constrained areas: application during a 1-year surveillance in the far north region of Cameroon. Am J Trop Med Hyg http://dx.doi.org/10.4269/ajtmh.15-0496.
22. Qadri F, Ali M, Chowdhury F, Khan AI, Saha A, Khan IA, Begum YA, Bhuiyan TR, Chowdhury MI, Uddin MJ, Khan JA, Chowdhury AI, Rahman A, Siddique SA, Asaduzzaman M, Akter A, Khan A, Ae You Y, Siddik AU, Saha NC, Kabir A, Riaz BK, Biswas SK, Begum F, Unicomb L, Luby SP, Cravioto A, Clemens JD. 2015. Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial. Lancet 386:1362-1371. http://dx.doi.org/10.1016/S0140-6736(15)61140-0.
23. Levinson KJ, De Jesus M, Mantis NJ. 2015. Rapid effects of a protective O-polysaccharide-specific monoclonal IgA on Vibrio cholerae agglutination, motility, and surface morphology. Infect Immun 83:1674-1683. http://dx.doi.org/10.1128/IAI.02856-14.
24. Grout L, Martinez-Pino I, Ciglenecki I, Keita S, Diallo AA, Traore B, Delamou D, Toure O, Nicholas S, Rusch B, Staderini N, Serafini M, Grais RF, Luquero FJ. 2015. Pregnancy outcomes after a mass vaccination campaign with an oral cholera vaccine in Guinea: a retrospective cohort study. PLoS Negl Trop Dis 9:e0004274. http://dx.doi.org/10.1371/journal.pntd.0004274.
25. Garmory HS, Leckenby MW, Griffin KF, Elvin SJ, Taylor RR, Hartley MG, Hanak JA, Williamson ED, Cranenburgh RM. 2005. Antibioticfree plasmid stabilization by operator-repressor titration for vaccine delivery by using live Salmonella enterica serovar Typhimurium. Infect Immun 73:2005-2011. http://dx.doi.org/10.1128/IAI.73.4.2005-2011.2005.
26. Emperador DM, Velasquez DE, Estivariz CF, Lopman B, Jiang B, Parashar U, Anand A, Zaman K. 2016. Interference of monovalent, bivalent, and trivalent oral poliovirus vaccines on monovalent rotavirus vaccine immunogenicity in rural Bangladesh. Clin Infect Dis 62:150-156. http://dx.doi.org/10.1093/cid/civ807.
27. Pitzer VE, Bilcke J, Heylen E, Crawford FW, Callens M, De Smet F, Van Ranst M, Zeller M, Matthijnssens J. 2015. Did large-scale vaccination drive changes in the circulating rotavirus population in Belgium? Sci Rep 5:18585. http://dx.doi.org/10.1038/srep18585.
28. Moon SS, Groome MJ, Velasquez DE, Parashar UD, Jones S, Koen A, van Niekerk N, Jiang B, Madhi SA. 2016. Prevaccination rotavirus serum IgG and IgA are associated with lower immunogenicity of live, oral human rotavirus vaccine in South African infants. Clin Infect Dis 62:157-165. http://dx.doi.org/10.1093/cid/civ828.
29. Kirkpatrick BD, Colgate ER, Mychaleckyj JC, Haque R, Dickson DM, Carmolli MP, Nayak U, Taniuchi M, Naylor C, Qadri F, Ma JZ, Alam M, Walsh MC, Diehl SA, Petri WA, Jr. 2015. The "Performance of Rotavirus and Oral Polio Vaccines in Developing Countries" (PROVIDE) study: description of methods of an interventional study designed to explore complex biologic problems. Am J Trop Med Hyg 92:744-751. http://dx.doi.org/10.4269/ajtmh.14-0518.
30. Fix AD, Harro C, McNeal M, Dally L, Flores J, Robertson G, Boslego JW, Cryz S. 2015. Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults. Vaccine 33:3766-3772. http://dx.doi.org/10.1016/j.vaccine.2015.05.024.
31. Shioda K, Kambhampati A, Hall AJ, Lopman BA. 2015. Global age distribution of pediatric norovirus cases. Vaccine 33:4065-4068. http://dx.doi.org/10.1016/j.vaccine.2015.05.051.
32. Becker-Dreps S, Bucardo F, Vilchez S, Zambrana LE, Liu L, Weber DJ, Pena R, Barclay L, Vinje J, Hudgens MG, Nordgren J, Svensson L, Morgan DR, Espinoza F, Paniagua M. 2014. Etiology of childhood diarrhea after rotavirus vaccine introduction: a prospective, populationbased study in Nicaragua. Pediatr Infect Dis J 33:1156-1163. http://dx.doi.org/10.1097/INF.0000000000000427.
33. Costantini VP, Cooper EM, Hardaker HL, Lee LE, Bierhoff M, Biggs C, Cieslak PR, Hall AJ, Vinje J. 2016. Epidemiologic, virologic, and host genetic factors of norovirus outbreaks in long-term care facilities. Clin Infect Dis 62:1-10. http://dx.doi.org/10.1093/cid/civ747.
34. Bernstein DI, Atmar RL, Lyon GM, Treanor JJ, Chen WH, Jiang X, Vinje J, Gregoricus N, Frenck RW, Jr., Moe CL, Al-Ibrahim MS, Barrett J, Ferreira J, Estes MK, Graham DY, Goodwin R, Borkowski A, Clemens R, Mendelman PM. 2015. Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. J Infect Dis 211:870-878. http://dx.doi.org/10.1093/infdis/jiu497.
35. Atmar RL, Bernstein DI, Lyon GM, Treanor JJ, Al-Ibrahim MS, Graham DY, Vinje J, Jiang X, Gregoricus N, Frenck RW, Moe CL, Chen WH, Ferreira J, Barrett J, Opekun AR, Estes MK, Borkowski A, Baehner F, Goodwin R, Edmonds A, Mendelman PM. 2015. Serological correlates of protection against a GII.4 norovirus. Clin Vaccine Immunol 22:923-929. http://dx.doi.org/10.1128/CVI.00196-15.
36. Dror G, Muhsen K. 24 November 2015. Helicobacter pylori infection and children's growth-An overview. J Pediatr Gastroenterol Nutr Epub ahead of print.
37. MAL-ED Network Investigators. 2014. The MAL-ED study: a multinational and multidisciplinary approach to understand the relationship between enteric pathogens, malnutrition, gut physiology, physical growth, cognitive development, and immune responses in infants and children up to 2 years of age in resource-poor environments. Clin Infect Dis 59(Suppl 4):S193-S206. http://dx.doi.org/10.1093/cid/ciu65.
38. WHO. 2009. Rotavirus vaccines: an update. Wkly Epidemiol Rec 84:533-540.
39. Breiman RF, Zaman K, Armah G, Sow SO, Anh DD, Victor JC, Hille D, Ciarlet M, Neuzil KM. 2012. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy studies of the oral pentavalent rotavirus vaccine. Vaccine 30(Suppl 1):A24-A29. http://dx.doi.org/10.1016/j.vaccine.2011.08.124.